Form 4: Director Hively Boosts TOI Stake with RSU Grants

The Oncology Institute Director Brad Hively increased his beneficial ownership by 74,074 shares through restricted stock unit grants.

Summary

• Brad Hively, a Director of The Oncology Institute, Inc. (TOI), acquired a total of 74,074 shares of common stock through restricted stock unit (RSU) grants on November 20, 2025.
• One grant involved 41,667 RSUs that will vest in full on the Issuer's 2026 annual stockholder meeting date, contingent on his continued service.
• Another grant involved 32,407 RSUs that were fully vested upon grant.
• Following these transactions, Hively's direct beneficial ownership of common stock increased to 697,054 shares.

Sentiment

Score: 7

Explanation: The filing indicates an increase in director ownership through equity grants, which is generally viewed positively as it aligns management interests with shareholders. The vesting schedule also incentivizes long-term commitment.

Positives

• Increased director ownership aligns management interests with shareholders.
• The grant of 32,407 fully vested RSUs immediately increases the director's stake.
• The grant of 41,667 performance-based RSUs (vesting in 2026) incentivizes continued service and long-term performance.

Future Outlook

The vesting schedule for 41,667 restricted stock units indicates an incentive for Brad Hively's continued service with The Oncology Institute, Inc. through the 2026 annual stockholder meeting.

Industry Context

Increased insider ownership, particularly through equity grants, is a common practice across various industries, including healthcare, to align executive and director incentives with long-term company performance and shareholder value. This type of compensation is standard for directors in publicly traded companies.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) as a form of executive and director compensation is a standard practice across the healthcare and broader public company landscape, comparable to practices at companies like HCA Healthcare (HCA) or Tenet Healthcare (THC) for incentivizing long-term commitment.
• The vesting schedule tied to continued service through an annual meeting date is a common mechanism to ensure retention and alignment, similar to equity compensation structures observed in many S&P 500 companies.

Stakeholder Impact

• Shareholders: Potentially positive, as increased director ownership can signal confidence and align interests.
• Employees: No direct impact mentioned.

Next Steps

• Brad Hively's continued service with The Oncology Institute, Inc. until the 2026 annual stockholder meeting for the vesting of 41,667 RSUs.

Key Dates

Recommendation

This Form 4 filing reports a routine equity grant to a director, increasing their beneficial ownership. While increased insider ownership is generally a positive signal of alignment, this specific transaction, being a compensation grant rather than an open market purchase, does not provide new fundamental information to warrant a change in investment thesis. It reinforces a 'hold' stance for investors already in the stock, as it's a standard governance practice.

Keywords

The Oncology Institute, TOI, Brad Hively, Form 4, Insider Trading, Restricted Stock Units, RSU, Director Ownership, Equity Grant, Beneficial Ownership